Since taking over from Dame June Raine as CEO of the Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025, Lawrence Tallon has big plans for the agency under his leadership.
On the medical device side, these aims include fostering a regulatory environment in the UK in which market access for innovative devices is more streamlined and efficient, with a disciplined, prudent approach towards evaluating devices that include technologic components such as artificial intelligence (AI), all while being a regulator that maintains a safe and rigorous approach to regulation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In this episode, Tallon discusses his top priorities for the agency over the coming years, the UK’s Early Access to Innovative Medical Devices (EAID) programme, AI, and the future of medical device regulation, among other topics.
You can listen to the full episode below:
